{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["5"],"submitter":["Javed M"],"pubmed_abstract":["<h4>Introduction</h4>Early kidney transplant failure has significant negative impact for individuals and healthcare systems. Contemporary data investigating early allograft failure are lacking. We undertook a retrospective observational cohort study of adult patients who underwent kidney transplantation at a single European centre.<h4>Methods</h4>We determined causes of allograft failure between 1 and 5 years after transplant and explored clinical variables present at 1 year that predicted allograft loss.<h4>Results</h4>591 patients (median age 50 years, 64.1% male, and 44% white) were included; 531 (89.8%) had graft survival and 60 (10.2%) had graft loss between 1- and 5-years. Rejection was the primary cause of graft failure in 24 (40%) cases and 54% had undetectable tacrolimus levels prior to failure event. Female sex, serum creatinine at 1 year, the occurrence of rejection, and undetectable tacrolimus levels were associated with increased odds of graft loss. In subsequent analysis of 787 patients alive with a functioning graft at 1 year, recipient age, serum creatinine, proteinuria, any rejection episode, and tacrolimus intrapatient variability (IPV) at 1 yearwere associated with an increased hazard of graft loss.<h4>Discussion</h4>Hence, graft losses were predominantly alloimmune mediated, often associated with non-adherence, and were predicted by tacrolimus IPV at 1 year."],"journal":["Frontiers in nephrology"],"pagination":["1666191"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12740892"],"repository":["biostudies-literature"],"pubmed_title":["Tacrolimus intrapatient variability and rejection are associated with inferior allograft outcomes after kidney transplantation."],"pmcid":["PMC12740892"],"pubmed_authors":["Khan AA","Evans RDR","Sanghera A","Needleman A","Javed M","Nagpal R","Jones G","Harber M","Fernando R","Hobill A","Thal N","Gage A","Karst F","Hmun M","Butler K","Shirling G"],"additional_accession":[]},"is_claimable":false,"name":"Tacrolimus intrapatient variability and rejection are associated with inferior allograft outcomes after kidney transplantation.","description":"<h4>Introduction</h4>Early kidney transplant failure has significant negative impact for individuals and healthcare systems. Contemporary data investigating early allograft failure are lacking. We undertook a retrospective observational cohort study of adult patients who underwent kidney transplantation at a single European centre.<h4>Methods</h4>We determined causes of allograft failure between 1 and 5 years after transplant and explored clinical variables present at 1 year that predicted allograft loss.<h4>Results</h4>591 patients (median age 50 years, 64.1% male, and 44% white) were included; 531 (89.8%) had graft survival and 60 (10.2%) had graft loss between 1- and 5-years. Rejection was the primary cause of graft failure in 24 (40%) cases and 54% had undetectable tacrolimus levels prior to failure event. Female sex, serum creatinine at 1 year, the occurrence of rejection, and undetectable tacrolimus levels were associated with increased odds of graft loss. In subsequent analysis of 787 patients alive with a functioning graft at 1 year, recipient age, serum creatinine, proteinuria, any rejection episode, and tacrolimus intrapatient variability (IPV) at 1 yearwere associated with an increased hazard of graft loss.<h4>Discussion</h4>Hence, graft losses were predominantly alloimmune mediated, often associated with non-adherence, and were predicted by tacrolimus IPV at 1 year.","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2026-06-06T05:46:44.247Z","creation":"2026-05-26T03:12:22.737Z"},"accession":"S-EPMC12740892","cross_references":{"pubmed":["41458304"],"doi":["10.3389/fneph.2025.1666191"]}}